Kiniksa Pharmaceuticals International, plc press release (KNSA): Q3 GAAP EPS of $0.56 beats by $0.21. – Revenue of $286M (+58.1% Y/Y) beats by $25.39M. – Kiniksa expects 2026 ARCALYST net product revenue of between $1.045 billion and $1.050 billion, compared to prior guidance
Kiniksa Pharmaceuticals International, Plc GAAP EPS of $0.56 Beats by $0.21, Revenue of $286M Beats by $25.39m
Kiniksa Pharmaceuticals International, plc press release (KNSA): Q3 GAAP EPS of $0.56 beats by $0.21. - Revenue of $286M (+58.1% Y/Y) beats by $25.39M. - Kiniksa expects 2026 ARCALYST net product revenue of between $1.045 billion and $1.050 billion, compared to prior guidance